Interaction-constrained 3D molecular generation using a diffusion model enables structure-based pharmacophore modeling for drug design

Read full text
Authors: Masami Sako, Nobuaki Yasuo, Masakazu Sekijima
Cited by: 2
References: 55

Abstract

Abstract A key challenge in structure-based drug design is generating three-dimensional molecules while preserving essential protein-ligand interactions. We propose DiffPharma, a structure-based pharmacophore modeling framework based on a conditional diffusion model, to generate molecules that satisfy specified interaction constraints. The proposed method incorporates a semantic fusion architecture that integrates multiple interaction-specific neural networks, each designed to capture distinct molecular interactions such as hydrogen bonds and hydrophobic interactions. Experimental results demonstrate that DiffPharma achieves a residue-level interaction similarity of up to 0.9, significantly outperforming baseline models. To assess the method’s generalizability, ligands were generated for AKT serine/threonine kinase 1 and serine β -lactamase, successfully preserving key interaction features. The effectiveness of the method is demonstrated through a practical case study targeting the SARS-CoV-2 main protease. Molecular dynamics simulations indicate that the generated molecules maintain both structural stability and key interactions comparable to those of a bioactive reference ligand. In addition, the molecular mechanics generalized Born surface area (MM/GBSA) calculations based on MD trajectories suggest that several generated molecules may exhibit relatively favorable binding tendencies compared with the reference. The implementation of the DiffPharma, including code and an execution environment on Google Colab, is available under the MIT license at GitHub: https://github.com/sekijima-lab/DiffPharma .

Fields of Study & Subjects

Computational Drug Discovery Methods Protein Structure and Dynamics Monoclonal and Polyclonal Antibodies Research

Publication details

Journal / source
npj Drug Discovery.
Publisher
Springer Science and Business Media LLC
Volume
3
Issue
1
Publication date
2 March 2026
Language
EN